Drug Database
Back to search

Finland· FI-REL-REL63376

PREVYMIS

A letermovir product containing letermovir, registered in Finland by Merck Sharp & Dohme B.V.. The same ATC class is registered in 15 of our 19 countries.

ATC J05AX18

Checked against Fimea (Finland) on

Informational only — not a medical device.

SOURCE REGISTER · FIFimea (Finland)normalisedPREVYMISATCJ05AX18REGISTER NO.FI-REL-REL63376PACKS LISTED0CHECKEDSeptember 27, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about letermovirAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Letermovir is registered in 15 of 19 countries.

Countries holding a registration under ATC J05AX18 (letermovir), each read from that country’s own register.

  • This record: Finland, from Fimea (Finland)
  • 10 of them publish a price we can compare per daily dose
Search letermovir products by name

Letermovir · ATC J05AX18

15 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Icelandprice
  • Ireland
  • Italyprice
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of letermovir costs, country by country.

Normalised to the WHO defined daily dose (0.48 g), the median price runs from $9.77 in France to $563.69 in Italy — a ×58 gap.

  • 3 markets with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown
Open the full comparison — free accountDrug prices for market access

Letermovir · price per daily dose (0.48 g)

USD · FX 28 Sept 2026

  • IT Italy$563.69
  • CH Switzerland$371.41
  • FR France$9.77
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

Fimea (Finland)
Active substance
Letermovir
Manufacturer
Merck Sharp & Dohme B.V.
Country
Finland (FI)
ATC code
J05AX18
ATC class
Letermovir
Defined daily dose
0.48 g, O
Reimbursed
Not published by this register
Source register
Fimea (Finland)
Last checked
September 27, 2026

Packs & prices · 0

No packs listed by the register for this record.

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

222 interactions on record for letermovir.

Graded by severity as the source publishes them — 38 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check letermovir against other medicinesHow interaction checks work

Letermovir · interactions on record

222 records

  • 38 severe
  • 172 moderate
  • 12 minor

Most severe, free to view

  • CisaprideA03FA02severe
  • NaloxegolA06AH03severe
  • EliglustatA16AX10severe
  • CilostazolB01AC23severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Letermovir in 15 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All letermovir products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Prevymis
  • Liechtenstein · Prevymis
  • Norway · Prevymis

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Fimea (Finland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/c208cf56-90e4-42c0-a803-8b496f324fcf
GET /v1/drugs/c208cf56-90e4-42c0-a803-8b496f324fcf?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "ddd": "0.48",
  "form": "rakeet, annospussi",
  "route": "Suun kautta",
  "ddd_unit": "g",
  "strength": "120 mg",
  "atc_label": "letermoviiri",
  "ma_number": null,
  "auth_status": "Myyntilupa myönnetty",
  "eu_ma_number": "EU/1/17/1245/006",
  "fimea_rel_id": "REL63376",
  "authorised_at": "2025-04-25"
}
API referenceMCP serverPlans

See everything about letermovir.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console